Skip to main content
Clinical Trials/NCT00002670
NCT00002670
Completed
Phase 3

Phase III Intergroup Trial of Surgery Followed by (1) Radiotherapy vs. (2) Radiochemotherapy For Resectable High Risk Squamous Cell Carcinoma of the Head and Neck

Radiation Therapy Oncology Group23 sites in 2 countries459 target enrollmentSeptember 1995

Overview

Phase
Phase 3
Intervention
low-LET electron therapy
Conditions
Head and Neck Cancer
Sponsor
Radiation Therapy Oncology Group
Enrollment
459
Locations
23
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether radiation therapy plus cisplatin is more effective than radiation therapy alone in treating patients with head and neck cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy plus cisplatin with radiation therapy alone in treating patients with head and neck cancer that has been removed during surgery.

Detailed Description

OBJECTIVES: I. Evaluate locoregional control rates, patterns of first failure, and overall and disease-free survival in patients with advanced squamous cell carcinoma of the head and neck at high risk of locoregional recurrence who are treated postoperatively with concurrent cisplatin and radiotherapy. II. Compare the toxicity of concurrent chemoradiotherapy vs. radiotherapy alone in the postoperative setting. OUTLINE: Randomized study. Arm I: Radiotherapy. Involved-field irradiation using Co60, 1-6 MV photons, or electrons. Arm II: Radiotherapy plus Single-Agent Chemotherapy. Irradiation as in Arm I; plus Cisplatin, CDDP, NSC-119875. PROJECTED ACCRUAL: 438 patients will be entered over approximately 5 years.

Registry
clinicaltrials.gov
Start Date
September 1995
End Date
November 2013
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Radiation therapy plus cisplatin

Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week) plus Cisplatin-100 mg/m2 i.v. on days 1,22 and 43 with radiation therapy.

Intervention: low-LET electron therapy

Radiation therapy

Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week)

Intervention: low-LET cobalt-60 gamma ray therapy

Radiation therapy

Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week)

Intervention: low-LET electron therapy

Radiation therapy

Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week)

Intervention: low-LET photon therapy

Radiation therapy plus cisplatin

Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week) plus Cisplatin-100 mg/m2 i.v. on days 1,22 and 43 with radiation therapy.

Intervention: chemotherapy

Radiation therapy plus cisplatin

Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week) plus Cisplatin-100 mg/m2 i.v. on days 1,22 and 43 with radiation therapy.

Intervention: cisplatin

Radiation therapy plus cisplatin

Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week) plus Cisplatin-100 mg/m2 i.v. on days 1,22 and 43 with radiation therapy.

Intervention: low-LET cobalt-60 gamma ray therapy

Radiation therapy plus cisplatin

Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week) plus Cisplatin-100 mg/m2 i.v. on days 1,22 and 43 with radiation therapy.

Intervention: low-LET photon therapy

Outcomes

Primary Outcomes

Not specified

Study Sites (23)

Loading locations...

Similar Trials